openPR Logo
Press release

Visceral Pain associated with GI disorders Market Outlook Report 2032 | Addex Therapeutics Ltd., AstraZeneca., Astellas Pharma, Allergan, Chromocell Corporation, Takeda, GIcare Pharma, AbbVie, Grunenthal GmbH

05-14-2024 05:28 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Visceral Pain associated with GI disorders Market Outlook Report 2032

Visceral Pain associated with GI disorders Market Outlook Report 2032

DelveInsight's "Visceral Pain associated with GI disorders Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Visceral Pain associated with GI disorders, historical and forecasted epidemiology as well as the Visceral Pain associated with GI disorders market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Visceral Pain associated with GI disorders market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Visceral Pain associated with GI disorders market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Visceral Pain associated with GI disorders treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Visceral Pain associated with GI disorders market.

Request for a Free Sample Report @ https://www.delveinsight.com/sample-request/visceral-pain-associated-with-gi-disorders-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Visceral Pain associated with GI disorders Overview

Visceral pain associated with gastrointestinal (GI) disorders refers to pain originating from internal organs within the abdomen, such as the stomach, intestines, liver, or gallbladder. Here's an overview of visceral pain related to GI disorders, including its causes, signs and symptoms, diagnosis, and treatment:
Causes:
Inflammation: Inflammatory conditions such as gastritis, pancreatitis, or inflammatory bowel diseases (e.g., Crohn's disease, ulcerative colitis) can cause irritation and pain in the GI tract.
Infection: GI infections caused by bacteria, viruses, or parasites can lead to inflammation and pain in affected organs.
Obstruction: Blockages in the GI tract due to conditions like bowel obstructions or gallstones can cause cramping and pain.
Functional Disorders: Conditions like irritable bowel syndrome (IBS) or functional dyspepsia can cause visceral pain without any identifiable structural abnormalities.
Ischemia: Reduced blood flow to the intestines, often due to conditions like mesenteric ischemia or ischemic colitis, can cause severe abdominal pain.
Nerve Sensitivity: Hypersensitivity of nerves in the GI tract can lead to heightened pain perception even with normal GI function, as seen in conditions like functional abdominal pain syndrome.
Signs and Symptoms:
Dull or Cramping Pain: Visceral pain is often described as a vague, dull, or cramping sensation rather than sharp or localized pain.
Referred Pain: Pain originating from one organ may be felt in another location, known as referred pain. For example, pain from the gallbladder may be felt in the right shoulder.
Nausea and Vomiting: GI disorders causing visceral pain often present with symptoms like nausea, vomiting, or a feeling of fullness.
Changes in Bowel Habits: Diarrhea, constipation, or changes in bowel movements may accompany visceral pain, especially in conditions like IBS.
Bloating and Gas: Abdominal bloating and increased gas production can contribute to discomfort in GI disorders associated with visceral pain.
Weight Loss: Chronic visceral pain associated with certain GI disorders may lead to unintended weight loss due to reduced appetite or difficulty eating.
Diagnosis:
Medical History and Physical Examination: A healthcare provider will assess symptoms, medical history, and perform a physical examination to evaluate for signs of GI disorders.
Imaging Tests: Imaging studies such as ultrasound, CT scans, or MRI may be ordered to visualize the internal structures of the abdomen and identify any abnormalities.
Endoscopic Procedures: Procedures like upper endoscopy, colonoscopy, or sigmoidoscopy may be performed to directly visualize the GI tract and obtain tissue samples for further evaluation.
Laboratory Tests: Blood tests, stool tests, or breath tests may be conducted to assess for signs of infection, inflammation, or other abnormalities in the GI system.
Treatment:
Medications: Depending on the underlying cause, medications such as proton pump inhibitors (PPIs), antacids, antibiotics, anti-inflammatory drugs, or medications to regulate bowel function may be prescribed.
Dietary Modifications: Avoiding trigger foods, increasing fiber intake, or following a low-FODMAP diet may help alleviate symptoms in conditions like IBS or functional dyspepsia.
Lifestyle Changes: Stress management techniques, regular exercise, and maintaining a healthy weight can help manage symptoms and improve overall GI health.
Procedures or Surgery: In some cases, procedures like endoscopic intervention, gallbladder removal (cholecystectomy), or surgery to remove obstructions may be necessary to address underlying GI disorders causing visceral pain.
Pain Management:
Analgesics: Over-the-counter pain relievers such as acetaminophen or nonsteroidal anti-inflammatory drugs (NSAIDs) may provide temporary relief from visceral pain.
Antispasmodics: Medications that help relax smooth muscles in the GI tract, such as dicyclomine or hyoscyamine, may be prescribed to alleviate cramping.
Nerve Modulators: Certain medications like tricyclic antidepressants or selective serotonin reuptake inhibitors (SSRIs) may help modulate nerve sensitivity and reduce visceral pain perception.
Multidisciplinary Approach:
Managing visceral pain associated with GI disorders often requires a multidisciplinary approach involving gastroenterologists, pain specialists, dietitians, and ment

Learn more about Visceral Pain associated with GI disorders, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Visceral Pain associated with GI disorders Market

The Visceral Pain associated with GI disorders market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Visceral Pain associated with GI disorders market trends by analyzing the impact of current Visceral Pain associated with GI disorders therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Visceral Pain associated with GI disorders market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Visceral Pain associated with GI disorders market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Visceral Pain associated with GI disorders market in 7MM is expected to witness a major change in the study period 2019-2032.

Request a sample and discover more about the report offerings at:
https://www.delveinsight.com/sample-request/visceral-pain-associated-with-gi-disorders-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Visceral Pain associated with GI disorders Epidemiology

The Visceral Pain associated with GI disorders epidemiology section provides insights into the historical and current Visceral Pain associated with GI disorders patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Visceral Pain associated with GI disorders market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Visceral Pain associated with GI disorders Epidemiology at: https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Visceral Pain associated with GI disorders Drugs Uptake

This section focuses on the uptake rate of the potential Visceral Pain associated with GI disorders drugs recently launched in the Visceral Pain associated with GI disorders market or expected to be launched in 2019-2032. The analysis covers the Visceral Pain associated with GI disorders market uptake by drugs, patient uptake by therapies, and sales of each drug.

Visceral Pain associated with GI disorders Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Visceral Pain associated with GI disorders market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Visceral Pain associated with GI disorders Pipeline Development Activities

The Visceral Pain associated with GI disorders report provides insights into different therapeutic candidates in Phase II and Phase III stages. It also analyses Visceral Pain associated with GI disorders key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Visceral Pain associated with GI disorders pipeline development activities at: https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Visceral Pain associated with GI disorders Therapeutics Assessment

Major key companies such as Addex Therapeutics Ltd., AstraZeneca., Astellas Pharma, Allergan, Chromocell Corporation, Takeda, GIcare Pharma, AbbVie, Grunenthal GmbH, and others are working proactively in the Visceral Pain associated with GI disorders Therapeutics market to develop novel therapies which will drive the Visceral Pain associated with GI disorders treatment markets in the upcoming years.

Learn more about the emerging therapies & key companies at: https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Visceral Pain associated with GI disorders Report Key Insights

1. Visceral Pain associated with GI disorders Patient Population
2. Visceral Pain associated with GI disorders Market Size and Trends
3. Key Cross Competition in the Visceral Pain associated with GI disorders Market
4. Visceral Pain associated with GI disorders Market Dynamics (Key Drivers and Barriers)
5. Visceral Pain associated with GI disorders Market Opportunities
6. Visceral Pain associated with GI disorders Therapeutic Approaches
7. Visceral Pain associated with GI disorders Pipeline Analysis
8. Visceral Pain associated with GI disorders Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Visceral Pain associated with GI disorders Market

Table of Contents

1. Key Insights
2. Executive Summary
3. Visceral Pain associated with GI disorders Competitive Intelligence Analysis
4. Visceral Pain associated with GI disorders Market Overview at a Glance
5. Visceral Pain associated with GI disorders Disease Background and Overview
6. Visceral Pain associated with GI disorders Patient Journey
7. Visceral Pain associated with GI disorders Epidemiology and Patient Population
8. Visceral Pain associated with GI disorders Treatment Algorithm, Current Treatment, and Medical Practices
9. Visceral Pain associated with GI disorders Unmet Needs
10. Key Endpoints of Visceral Pain associated with GI disorders Treatment
11. Visceral Pain associated with GI disorders Marketed Products
12. Visceral Pain associated with GI disorders Emerging Therapies
13. Visceral Pain associated with GI disorders Seven Major Market Analysis
14. Attribute Analysis
15. Visceral Pain associated with GI disorders Market Outlook (7 major markets)
16. Visceral Pain associated with GI disorders Access and Reimbursement Overview
17. KOL Views on the Visceral Pain associated with GI disorders Market
18. Visceral Pain associated with GI disorders Market Drivers
19. Visceral Pain associated with GI disorders Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Get the Detailed TOC of the Visceral Pain associated with GI disorders Market report here: https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Us:

Kritika Rehani
info@delveinsight.com
+91-9650213330
www.delveinsight.com

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Visceral Pain associated with GI disorders Market Outlook Report 2032 | Addex Therapeutics Ltd., AstraZeneca., Astellas Pharma, Allergan, Chromocell Corporation, Takeda, GIcare Pharma, AbbVie, Grunenthal GmbH here

News-ID: 3496294 • Views:

More Releases from DelveInsight Business Research LLP

Alpha-1 Protease Inhibitor Deficiency Market Size 2032: CSL Behring, Grifols Therapeutics LLC, Arriva Pharmaceuticals, Inc., Takeda, Kamada Ltd, and others.
Alpha-1 Protease Inhibitor Deficiency Market Size 2032: CSL Behring, Grifols The …
DelveInsight's "Alpha-1 Protease Inhibitor Deficiency Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Alpha-1 Protease Inhibitor Deficiency, historical and forecasted epidemiology as well as the Alpha-1 Protease Inhibitor Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Key Takeaways from the Alpha-1 Protease Inhibitor Deficiency Market Research Report • The increase in Alpha-1 Protease Inhibitor Deficiency Market Size
Amyloidosis Market Size Report 2032: Attralus Inc., Novotech Pty Limited, Criterium Inc., Amgen, Millennium Pharmaceuticals Inc., Johnson & Johnson Pharmaceuticals, Intellia Therapeutiscs, Regeneron Pharmaceuticals, Akcea Therapeutics, GlaxoSmithKline, Un
Amyloidosis Market Size Report 2032: Attralus Inc., Novotech Pty Limited, Criter …
DelveInsight's "Amyloidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Amyloidosis, historical and forecasted epidemiology as well as the Amyloidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Key Takeaways from the Amyloidosis Market Research Report • The increase in Amyloidosis Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies
Basal Cell Nevus Syndrome Market Size Report 2032: Latest FDA Approvals, Emerging Drugs | Sol-Gel Technologies, Ltd, Premier Research Group plc, PellePharm Inc., DUSA Pharmaceuticals, Inc., Ascend Biopharmaceuticals Inc., Genentech Inc., Palvella Therapeu
Basal Cell Nevus Syndrome Market Size Report 2032: Latest FDA Approvals, Emergin …
DelveInsight's "Basal Cell Nevus Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Basal Cell Nevus Syndrome, historical and forecasted epidemiology as well as the Basal Cell Nevus Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Key Takeaways from the Basal Cell Nevus Syndrome Market Research Report • The increase in Basal Cell Nevus Syndrome Market Size
Biliary Atresia Market Size Report 2032: Latest FDA Approvlas and Pipeline ReportMirium Pharmaceuticals, Albireo, Intercept Pharmaceuticals, and others. Promising Biliary Atresia Therapies in the various stages of development include BYLVAY, LIVMARLI, and
Biliary Atresia Market Size Report 2032: Latest FDA Approvlas and Pipeline Repor …
DelveInsight's "Biliary Atresia Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Biliary Atresia, historical and forecasted epidemiology as well as the Biliary Atresia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. Key Takeaways from the Biliary Atresia Market Research Report • The increase in Biliary Atresia Market Size is a direct consequence of the increasing

All 5 Releases


More Releases for Pain

Global Pain Management Devices Market Study Analysis: Adoption Of Pain Managemen …
The fast-food market size was valued at $ billion in 2020 and is estimated to reach $ billion by 2028, growing at a CAGR of 6.3% during the forecast period. Pain is an unpleasant sensation and emotional experience caused due to actual or potential tissue damage or illness. Pain can be caused due to accidental injuries, or due to diseases like osteoarthritis, chronic arthritis, diabetic neuropathy, multiple sclerosis, stomach ulcer,
Flexotone Joint Pain Relief Reviews: Get Relief from Joint Pain & Arthritis
Joint pain & inflammation has come to be an instead usual problem among older consumers, as well as they are frequently entrusted to identify exactly how to deal with these problems with a topical cream or resting. Nevertheless, the makers behind Flexotone think that the reason behind this concern has every little thing to do with something that takes place within the joints. This trouble triggers unbelievable pain; however Big
Nerve Pain Treatment: 3 Top Neuropathy Pain Relief Pills
Neuropathy affects your extremities or nerves by producing tingling, discomfort, or numbness. Diabetics frequently suffer from neuropathy. According to the American Diabetes Association, around 65 percent of people suffering from diabetes face varying degrees of nerve damage, which results in diabetic neuropathy. Neuropathy can also occur due to different reasons, like alcoholism, trauma, or autoimmune disorders. Some people acquire neuropathy due to physical injury to their nerves, for instance. Others have
Post-operative Pain Management Market 2018 by Pain Type - Acute Pain, Moderate P …
Post-operative Pain Management Market 2018 Research Report implements an exhaustive study on Market Research Future. This Report Cover Key Market Driver, market size, growth rate, opportunities, market Dynamics and Overall Analysis. And also cover the other information such as Post-operative Pain Management Market trends, Prominent players, chapter-wise Description followed by various user perceptions and Forecast till 2023. Global Post-operative Pain Management Market - Overview Post-operative pain management is the most important part
Opioids – Reducing body pain but increasing pain for regulatory authorities
Opioids are drugs primarily prescribed for pain management and treatment of diarrhea and cough. Opioid drugs are of two types namely, agonist and antagonist. Codeine, Fentanyl, Meperidine, Methadone, Morphine, Hydrocodone, Diphenoxylate, Hydromorphone, Methylphenidate, Oxycodone, and Oxymorphone are classified as agonists, while Buprenorphine, Naloxone, Naltrexone, Methylnaltrexone, and Nalbuphine are classified as antagonists. Due to easy availability of opioids, these drugs are rampantly overused globally and the situation is more critical in
Middle East Tapentadol Market by Therapeutic Application Pain Management Neuropa …
Tapentadol is an opioid analgesic, indicated for severe pain management, on a daily or around the clock need for treatment and long-term opioid treatment, for which alternative treatment options are inadequate. Tapentadol is also indicated for neuropathic pain associated with diabetic peripheral neuropathy. It is widely used for management of acute, chronic, and cancer related pain among patients and is available legally on prescription. Nucynta ER is the first and